HOUSTON, Jan. 14, 2005 (PRIMEZONE) -- Eternal Technologies Group Inc. (OTCBB:ETLT) today announced that it has received a request from a new customer to breed sika in the Peoples' Republic of China using the company's proprietary embryo transfer techniques.
Sika, small deer that originate from Asia, weigh approximately 50-100 pounds and are approximately 2 1/2 feet at the shoulder. Products made from its antler, tendon and blood contain organic substances known to slow down the aging process while reducing symptoms of fatigue. These products have been used by Chinese medical professionals for thousands of years without any side effects.
Eternal's new customer operates a farm of 24,000 hectares which is approved as a state level area of integrated farming. The customer has been in business for 30 years and is one of the largest breeders of sika in mainland China. The low rate of sika breeding using natural methods has created a mandate by sika breeders in mainland China to adopt new embryo transfer techniques to meet the growing demand for sika in the healthcare industry. Eternal has set up a research team to determine the most efficient breeding protocol using the company's proprietary embryo transfer techniques.
"We understand that many people in the West do not understand the importance of sika in the Chinese healthcare system," said Mr. JiJun Wu, Chairman of Eternal Technologies Group Inc.
Mr. Wu further commented, "In the same way that it took ginseng thousand of years to be discovered by Western medical practitioners, the importance of organic substances only found in sika still have not been discovered in the West. The ability of these organic substances found in sika to slow down or reduce some of the human body's processes have been demonstrated for thousands of years."
The information contained in this press release should be read in connection with the company's Quarterly Report filed on Form 10-QSB for the quarter ended September 30, 2004 and its Annual Report filed on Form 10-KSB for the year ended December 31, 2003.
About Eternal Technologies
Eternal is a major agricultural genetics and biopharmaceutical R&D firm operating in China with the support of the Chinese Government. Eternal's animal breeding division has a strong asset base, cash position and net income. Eternal has become one of China's leading institutions for biopharmaceutical and biotech research, pure breed cultivation and breed stock production. The Company has secured a key market niche by commercializing gene engineering technologies and providing superior breeding stock, allowing China's citizens the ability to improve their living standards. With the world's largest population, a double-digit national growth rate and entry into the WTO, Eternal Technologies has a playing field set for tremendous opportunity. As a prominent player in the agricultural genetics industry, cash in the bank and an untapped market, Eternal has the potential to become a major player in China's national growth.
In addition, Eternal has recently completed the acquisition of E-Sea Biomedical Engineering Co. International, Ltd. As a result of the acquisition, Eternal now owns an extremely promising breast cancer detection technology which can be offered at fractions of the costs of competing technologies.